Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Critically Ill Adults With Coronavirus Disease 2019 in New Orleans and Care With an Evidence-Based Protocol

David R. Janz, MD; Scott Mackey, DO; Nirav Patel, MD; Beau P. Saccoccia, MD; Michelle St. Romain, MD; Bethany Busack, MD; Hayoung Lee, MD; Lana Phan, MD; Jordan Vaughn, MD; David Feinswog; Ryan Chan; Lauren Auerbach, MD; Nicholas Sausen, MD; Joseph Grace; Marian Sackey, MD; Anushka Das; Angellica O. Gordon; Jennifer Schwehm, RN, MSN; Robin McGoey, MD; Kyle I. Happel, MD; and Stephen P. Kantrow, MD

BACKGROUND: Characteristics of critically ill adults with coronavirus disease 2019 (COVID-19) in an academic safety net hospital and the effect of evidence-based practices in these patients are unknown.

RESEARCH QUESTION: What are the outcomes of critically ill adults with COVID-19 admitted to a network of hospitals in New Orleans, Louisiana, and what is an evidence-based protocol for care associated with improved outcomes?

STUDY DESIGN AND METHODS: In this multi-center, retrospective, observational cohort study of ICUs in four hospitals in New Orleans, Louisiana, we collected data on adults admitted to an ICU and tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between March 9, 2020 and April 14, 2020. The exposure of interest was admission to an ICU that implemented an evidence-based protocol for COVID-19 care. The primary outcome was ventilator-free days.

RESULTS: The initial 147 patients admitted to any ICU and tested positive for SARS-CoV-2 constituted the cohort for this study. In the entire network, exposure to an evidence-based protocol was associated with more ventilator-free days (25 days; 0-28) compared with non-protocolized ICUs (0 days; 0-23, \(P = 0.005\)), including in adjusted analyses (\(P = 0.02\)). Twenty patients (37%) admitted to protocolized ICUs died compared with 51 (56%; \(P = 0.02\)) in non-protocolized ICUs. Among 82 patients admitted to the academic safety net hospital’s ICUs, the median number of ventilator-free days was 22 (interquartile range, 0-27) and mortality rate was 39%.

INTERPRETATION: Care of critically ill COVID-19 patients with an evidence-based protocol is associated with increased time alive and free of invasive mechanical ventilation. In-hospital survival occurred in most critically ill adults with COVID-19 admitted to an academic safety net hospital’s ICUs despite a high rate of comorbidities.

KEY WORDS: ARDS; COVID-19; critical care
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions worldwide and caused coronavirus disease 2019 (COVID-19) in hundreds of thousands. COVID-19 is associated with a high rate of critical illness, morbidity, and mortality. Click or tap here to enter text. Specifically, acute respiratory failure requiring respiratory support, the development of ARDS, acute kidney injury, and shock are common in critically ill adults with COVID-19. Outcomes of critically ill adults with COVID-19 admitted to an academic safety net hospital are unknown.

The syndromes caused by COVID-19, specifically acute respiratory failure and ARDS, have evidence- and guideline-based management recommendations. First, in some patient populations the use of certain respiratory support devices, such as noninvasive positive-pressure ventilation (NIPPV), decrease the need for tracheal intubation and is recommended for consideration in patients with COVID-19. Second, if patients do require endotracheal intubation and develop ARDS, the provision of low tidal volume ventilation, and a conservative fluid management strategy improve the number days alive and free of invasive mechanical ventilation. If ARDS is moderate to severe, treatment with prone positioning and higher amounts of positive end-expiratory pressure (PEEP) may improve survival. When patients with respiratory failure have improved, liberation from sedatives and invasive ventilation by providing support with NIPPV may decrease the need for reintubation. However, some have argued against using these interventions in critically ill adults with COVID-19 because of unknown effectiveness and potential harm.

We conducted a retrospective, cohort, observational study of critically ill adults with COVID-19 admitted to a network of four hospitals. Some ICUs in this network implemented an evidence-based pilot protocol that provided guidance on the management of the patient with acute respiratory failure and ARDS. We hypothesized that protocol implementation would be associated with increased ventilator-free days in critically ill adults with COVID-19.

**Methods**

**Study Design and Oversight**

We conducted a retrospective cohort study of all initial patients admitted to a group of four hospitals in New Orleans, Louisiana, who were critically ill and tested positive for SARS-CoV-2 between March 9, 2020 and April 14, 2020. The study was approved with a waiver of informed consent by the institutional review board at Louisiana State University School of Medicine New Orleans.

**Study Sites and Patient Population**

The retrospective study was conducted using quality improvement data collected by a network of four hospitals located in New Orleans, Louisiana. The study population consisted of the first 147 critically ill adults who were admitted to any ICU in the network of hospitals and had a positive nasopharyngeal swab for SARS-CoV-2. The current observational study was conducted with data entered into the database at the time of analysis and consisted of patients admitted to any ICU from March 9, 2020 through April 14, 2020. At the time of submission, 28-day hospital vital status or discharge status was known on all patients. Seven patients remain alive and hospitalized beyond 28 days. Data included demographics, comorbidities, laboratory values, ventilator parameters, medication administration, and in-hospital clinical outcomes.

As a potential quality improvement initiative and during the observational period, two ICUs located in an academic, safety-net hospital within the network implemented an evidence-based pilot protocol to guide the care of the critically ill adult with COVID-19. The feasibility, effectiveness, and resource availability aspects of this protocol were unknown, specifically related to the use of noninvasive positive-pressure ventilation; therefore, implementation occurred in two ICUs during the observational period before expanding to all ICUs. This protocol consisted of guidance on the management of all phases of acute respiratory failure, including the prevention of tracheal intubation, applying evidence-based ARDS care to intubated patients, and guidance on extubation. Protocol development occurred via an iterative process of literature review regarding the care of the ARDS patient, protocol development meetings with stakeholders, and development of bedside algorithms. Implementation of this protocol occurred via dissemination of these algorithms to bedside providers in the pilot ICUs, teaching of the evidence supporting recommendations, multiple daily checks by protocol champions to ensure adherence, and institutional oversight. The pilot protocol was available to all ICUs in the network; however, the implementation described here only occurred in selected ICUs. None of the ICUs in the network had specific criteria for ICU admission. All ICUs in the network of hospitals had daytime staffing by board-certified intensivists; however, few ICUs had house staff or advanced-practice practitioners, and none had electronic ICU coverage.

**Study Outcomes and Statistical Analysis**

The primary comparison in this cohort study was between patients admitted to an ICU that implemented the pilot care protocol vs patients admitted to an ICU that did not undergo implementation during the observation period. The primary analysis in this cohort was ventilator-free days, calculated by 28 minus the number of days the patient was tracheally intubated, with a value of zero assigned to patients who died in the hospital. Ventilator-free days (VFDs) was chosen as the primary outcome, because this is a well-validated, patient-centered outcome commonly chosen in studies of acute respiratory failure. Secondary outcomes included 28-day inhospital mortality, need for tracheal intubation, and need for renal replacement therapy. We also analyzed the primary outcome of VFDs and processes of care over the course of the observational period to see whether this outcome improved over time. Finally, given we only had access to data that were already entered into this
database and could not exclude the possibility of patients not yet entered into the database late in the observation period, we performed a sensitivity analysis for the primary outcome of VFDs restricted to patients admitted in the first calendar month since the diagnosis of the index ICU patient.

Most data were not normally distributed and, therefore, were reported as median values with interquartile range for continuous variables and frequencies for categorical variables. Univariate analyses of continuous variables were conducted with Mann-Whitney U tests and \( \chi^2 \) tests for categorical variables. A linear regression model was also used to analyze the dependent variable of VFDs with the independent variables of pilot protocol implementation, APACHE II score, age, and the ratio of PAO\(_2\)/FiO\(_2\) on ICU admission. One-way repeated measures analysis of variance was used to compare groups regarding repeated measures over time. IBM SPSS Statistics (version 25) was used for statistical analysis. A two-sided significance value of .05 was used for statistical significance. The STROBE Guidelines for Reporting Observational Studies were followed in drafting this manuscript.21

## Results

### Baseline Characteristics

Of 214 critically ill adults who were admitted to a network ICU and tested for SARS-CoV-2 during the observation period, 147 patients tested positive and constituted the primary cohort for the current analysis (Fig 1). Regarding patients exposed to protocol implementation or not, there were statistically significant imbalances in location before ICU admission, asthma, and end-stage renal disease. Laboratory values on ICU admission were not statistically significantly different other than a lower PAO\(_2\)/FiO\(_2\) ratio in patients not exposed to protocol implementation (Table 1).

### Management in ICUs with Pilot Protocol Implementation

A total of 14 (25%) patients in the pilot protocol group never required intubation compared with 16 (17%, \( P = .15 \)) patients admitted to ICUs without pilot protocol implementation. In patients never requiring intubation and in pilot protocol ICUs, 57% were supported with noninvasive positive pressure ventilation (e-Table 1). In intubated patients, there was no statistically significant difference in tidal volumes provided, FiO\(_2\) to PEEP ratio, or receipt of prone positioning over the first 5 days of ICU care (e-Figs 1, 2, 3). Patients cared for in ICUs undergoing protocol implementation received higher mean daily doses of furosemide over the first 5 days of ICU care (\( P = .005 \)) (e-Fig 4). At the time of extubation, 57% of patients were extubated to noninvasive positive pressure ventilation (Table 2).

### Primary Outcome

The median number of VFDs in patients exposed to pilot protocol implementation was 25 days (0-28) compared with 0 days (0-23, \( P = .005 \)) in patients not exposed to pilot protocol implementation (Table 2). Pilot protocol

---

**Figure 1 – Study flow diagram.**
| Characteristic                          | Safety Net Hospital SARS CoV-2 + ICU Patients (n = 82) | Network ICUs with Quality Improvement Pilot Protocol Implementation (n = 54) | Network ICUs without Quality Improvement Pilot Protocol Implementation (n = 93) | P (Comparison Between Pilot Protocol Groups) |
|----------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------|
| Age, y                                 | 61 (50-71)                                             | 62 (50-74)                                                                   | 65 (54-76)                                                                      | .25                                         |
| Men, No. (%)                           | 38 (46%)                                               | 25 (46%)                                                                     | 46 (49%)                                                                        | .71                                         |
| African American, No. (%)              | 77 (93%)                                               | 51 (94%)                                                                     | 75 (80%)                                                                        | .12                                         |
| BMI                                    | 35 (30-43)                                             | 35 (29-41)                                                                   | 32 (28-38)                                                                      | .24                                         |
| APACHE II Score                        | 13 (10-18)                                             | 12 (9-16)                                                                    | 15 (9-20)                                                                       | .09                                         |
| SOFA Score                             | 4 (2-6)                                                | 4 (3-5)                                                                      | 4 (3-6)                                                                         | .43                                         |
| Location Before ICU Admission, No. (%) |                                                        |                                                                              |                                                                                 | .003                                        |
| ED                                     | 44 (53%)                                               | 32 (59%)                                                                     | 38 (40%)                                                                        |                                             |
| Hospital floor                         | 35 (42%)                                               | 19 (35%)                                                                     | 55 (59%)                                                                        |                                             |
| Outside-of-network hospital             | 3 (3%)                                                 | 3 (5%)                                                                       | 0                                                                               |                                             |
| Comorbidities, No. (%)                 |                                                        |                                                                              |                                                                                 |                                             |
| Hypertension                           | 71 (86%)                                               | 45 (83%)                                                                     | 70 (75%)                                                                        | .25                                         |
| Diabetes mellitus                      | 47 (57%)                                               | 29 (53%)                                                                     | 43 (46%)                                                                        | .45                                         |
| Cardiovascular disease                 | 29 (35%)                                               | 16 (29%)                                                                     | 30 (32%)                                                                        | .76                                         |
| Heart failure                          | 16 (19%)                                               | 9 (16%)                                                                      | 14 (15%)                                                                        | .81                                         |
| Solid malignancy                       | 7 (8%)                                                 | 4 (7%)                                                                       | 14 (15%)                                                                        | .16                                         |
| COPD                                   | 15 (18%)                                               | 11 (20%)                                                                     | 9 (9%)                                                                          | .08                                         |
| Asthma                                 | 19 (23%)                                               | 14 (25%)                                                                     | 9 (9%)                                                                          | .01                                         |
| Chronic kidney disease                 | 22 (26%)                                               | 14 (25%)                                                                     | 28 (30%)                                                                        | .56                                         |
| End-stage renal disease                | 3 (3%)                                                 | 0                                                                            | 9 (9%)                                                                          | .01                                         |
| Chronic liver disease                  | 2 (2%)                                                 | 2 (3%)                                                                       | 2 (2%)                                                                          | .58                                         |
| Laboratory data on ICU admission       |                                                        |                                                                              |                                                                                 |                                             |
| D-dimer (n = 67)                       | 483 (250-948)                                          | 469 (278-867)                                                                | 332 (4-1330)                                                                    | .32                                         |
| Ferritin (n = 81)                      | 678 (345-1524)                                         | 556 (220-1359)                                                               | 695 (408-2108)                                                                  | .06                                         |
| C-reactive protein (n = 86)            | 15.8 (11.4-22.2)                                       | 15.4 (12.1-22.2)                                                             | 16.1 (11.1-24.6)                                                                | .92                                         |
| WBC count (n = 136)                    | 9.3 (7.3-12)                                           | 8.9 (7.2-12.3)                                                               | 9.05 (6.25-12.47)                                                               | .79                                         |
| Absolute neutrophil count (n = 116)    | 7,500 (5,500-9,840)                                    | 7,550 (5,375-10,600)                                                         | 7,235 (5,277-10,225)                                                            | .76                                         |
| Absolute lymphocyte count (n = 116)    | 915 (700-1,325)                                        | 940 (700-1,410)                                                              | 920 (670-1,400)                                                                 | .6                                          |

(Continued)
implementation remained associated with increased VFDs after adjustment for APACHE II score alone (P = .007; Fig 2) and after adjustment for APACHE II score, age, and PaO2/FIO2 on ICU admission (P = .02) (e-Table 2). In a sensitivity analysis restricted to the first calendar month of ICU admissions for COVID-19, pilot protocol implementation remained associated with increased VFDs (23 days, 0-27) compared with no pilot protocol implementation (0 days, 0-22) in both unadjusted (P = .03) and adjusted analyses for APACHE II score, age, and PaO2/FIO2 ratio on ICU admission (beta, 5.28; 95% CI, 0.1-10.4; P = .04).

Data given as median (25th percentile-75th percentile) or number (percentage) of patients. P value = Mann-Whitney U test for continuous variables, \( \chi^2 \) test for categorical variables, and \( \chi^2 \) test for a trend for categorical variables with more than two groups.

APACHE = acute physiology and chronic health evaluation; SOFA = Sequential Organ Failure Assessment.

TABLE 1 | (Continued)

| Characteristic                      | Safety Net Hospital SARS CoV-2 + ICU Patients (n = 82) | Network ICUs with Quality Improvement Pilot Protocol Implementation (n = 54) | Network ICUs without Quality Improvement Pilot Protocol Implementation (n = 93) | P (Comparison Between Pilot Protocol Groups) |
|-------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------|
| Neutrophil to lymphocyte ratio      | 7.1 (4.6-11.4)                                         | 6.8 (4.4-10.5)                                                             | 8 (4.6-12.6)                                                                   | .3                                          |
| Creatinine kinase                   | 181 (89-564)                                           | 164 (88-403)                                                               | 342 (91-896)                                                                  | .28                                         |
| BUN                                 | 20 (14-42)                                             | 19 (13-39)                                                                 | 26 (13-42)                                                                     | .46                                         |
| Creatinine                          | 1.26 (0.93-1.88)                                       | 1.25 (0.83-1.71)                                                           | 1.31 (0.95-2.25)                                                              | .29                                         |
| Lactate dehydrogenase               | 416 (315-513)                                          | 428 (307-520)                                                              | 451 (372-634)                                                                 | .1                                          |
| Triglyceride                        | 138 (84-327)                                           | 138 (84-327)                                                               | 134 (93-250)                                                                   | .84                                         |
| Fibrinogen                          | 700 (700-700)                                          | 700 (700-700)                                                              | 666 (412-700)                                                                 | .23                                         |
| PaO2/FIO2 ratio                     | 112 (78-199)                                           | 116 (94-265)                                                               | 101 (55-154)                                                                   | .02                                         |

Data given as median (25th percentile-75th percentile) or number (percentage) of patients. P = Mann-Whitney U test for continuous variables and \( \chi^2 \) test for categorical variables.

TABLE 2 | Clinical Outcomes

| Outcome                                      | Safety Net Hospital SARS CoV-2 + ICU Patients (n = 82) | Network ICUs with Quality Improvement Pilot Protocol Implementation (n = 54) | Network ICUs without Quality Improvement Pilot Protocol Implementation (n = 93) | Relative Risk (95% Confidence Interval) | P (Comparing Protocol Implementation Groups) |
|----------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|
| Ventilator-free days                         | 22 (0-27)                                              | 25 (0-28)                                                                  | 0 (0-23)                                                                        | .005                                        |                                             |
| In-hospital mortality, No. (%)               | 32 (39%)                                               | 20 (37%)                                                                   | 51 (56%)                                                                        | 0.67 (0.48-0.94)                           | .02                                         |
| In-hospital mortality in only patients ever tracheally intubated, No. (%) | 30 (50%)                                               | 18 (47%)                                                                   | 50 (68%)                                                                        | 0.68 (0.47-0.99)                           | .03                                         |
| Need for renal replacement therapy, No. (%)  | 22 (26%)                                               | 8 (14%)                                                                    | 36 (38%)                                                                        | 0.38 (0.19-0.76)                           | .002                                        |

Data given as median (25th percentile-75th percentile) or number (percentage) of patients. P = Mann-Whitney U test for continuous variables and \( \chi^2 \) test for categorical variables.
Secondary Outcomes

Exposure to pilot protocol implementation was associated with a decreased 28-day in-hospital mortality for all-comers (37% vs 56%; \(P = .02\)) as well as for those who required invasive mechanical ventilation (47% vs 68%; \(P = .03\)). Pilot protocol implementation was also associated with a reduction in need for any type of renal replacement therapy (14% vs 38%; \(P = .002\)) (Table 2).

Regarding the entire cohort of the initial 147 patients admitted to any network ICU, VFD increased over time from the date of the first SARS-CoV-2 positive diagnosis until the end of the observation period (e-Fig 5). Over this same period, severity of illness on ICU admission did not significantly decrease (e-Fig 6). Process of care measures that improved over this period include increasing amounts of PEEP for respective FiO\(_2\) provision (e-Fig 7), decrease in tracheal intubations, and an increase in use of NIPPV before intubation or if never intubated in pilot protocol implementation ICUs (Fig 3). There was no significant change in the provision of tidal volumes nor in mean cumulative furosemide dosing over this period (e-Fig 8). In pilot protocol implementation ICUs with the highest rates of NIPPV use, only one nurse is known to have tested positive for SARS-CoV-2.

Characteristics of Patients Admitted to the Network Safety-Net Hospital

A total of 82 patients were admitted to ICUs in the Network’s academic safety net hospital. Patients admitted to this academic safety net hospital had a median age of 61 years (50-71) with a BMI of 35 (30-43), and 93% were African American. Additionally, patients admitted to this academic safety net hospital had high rates of hypertension (86%) and diabetes mellitus (57%) (Table 1). In these 82 patients, the median number of ventilator-free days was 22 (interquartile range, 0-27), and the mortality rate was 39% (Table 2).

Discussion

Most critically ill adults with COVID-19 admitted to an academic safety net hospital survived to hospital discharge, and 21% never required tracheal intubation. Implementation of a pilot patient care protocol was associated with significantly more ventilator-free days and higher survival. Ventilator-free days increased over the duration of the observation, along with an increase in NIPPV use, higher PEEP, and decreased tracheal intubation rates. To our knowledge, this is the first description of the outcomes of patients with COVID-19 patients in an academic safety net hospital and of the associated treatment effect of evidence- and guideline-based interventions for patients with ARDS in a population with COVID-19.

Safety net hospitals, defined as those that by obligation or mission provide health care to patients regardless of insurance status or ability to pay, are commonly also academic hospitals and frequently care for a patient population with high rates of co-morbidities.\(^{22,23}\) We observed these same high rates of co-morbidities in the patient population admitted to the academic safety net hospital during this study. However, most of these critically ill patients with COVID-19 had good clinical...
outcomes such as survival to hospital discharge. The cause of the improved outcomes in this patient population is unknown. Mortality rates from the current study are not directly comparable to reported mortality rates in other studies of COVID-19, because the number of measured and unmeasured differences between geographically separate hospitals are numerous.

At the time of this observational study, there were no treatments of SARS-CoV-2 known to cause an improvement in patient-centered outcomes. However, there were numerous evidence- and guideline-based interventions that have been used for decades in critical care to improve outcomes in patients with the syndrome caused by COVID-19, such as acute respiratory failure and ARDS. Support of respiratory failure with NIPPV has been shown to prevent intubation in a number of patient populations. Decreased mortality and ventilator utilization have occurred in past trials of low tidal volume ventilation, a conservative fluid management strategy, prone positioning, application of higher amounts of PEEP, spontaneous awakening and breathing trials, and use of NIPPV at the time of extubation. As part of a quality improvement initiative to increase our surge capacity of ventilators and ICU rooms and improve outcomes of patients with COVID-19, guidance was created based on this evidence and implemented as a pilot protocol in a subgroup of ICUs. As previously noted, the pilot protocol was available to all ICUs in the network but only underwent implementation in selected ICUs. The availability of the protocol to all ICUs should have biased our results toward the null; however, a statistically significant associated effect remained despite this bias.

The current study describes the association between pilot protocol implementation and increased VFDs in patients with COVID-19, whether this protocol caused improved outcomes is unknown. Which aspects of the protocol may have provided benefit to patients and which aspects had little effect are also unknown. We observed an increase in the number of VFDs over time.
in all network ICUs since the index case, despite no apparent decrease in measures of severity of illness over the same period. Regarding protocol items based on the evidence listed, provision of low tidal volume ventilation did not improve over time. However, low tidal volume ventilation was provided to most of the patients regardless of protocol guidance. Cumulative daily furosemide dose also seems unlikely to explain the effect of increasing VFDs over time. Protocol-recommended items that did increase over the observation period included the level of PEEP, avoidance of tracheal intubation, and use of NIPPV before intubation or if never intubated.

Although some have recommended avoidance of respiratory support devices such as NIPPV because of potential risk of aerosolization of SARS-CoV-2,¹⁷ the risk of transmission of SARS-CoV-2 to health-care providers caring for patients receiving NIPPV is unknown.⁹ Click or tap here to enter text. In the current study, only one nurse and no respiratory therapists in the ICUs with the highest rate of NIPPV use are known to have tested positive for SARS-CoV-2.

The current study has a number of limitations. First, the observational nature of the study may introduce selection and other biases into the analyses that were incompletely controlled for in adjusted analyses. Second, there may have been unmeasured differences between groups other than pilot protocol implementation, because this observation occurred across a network of hospitals serving different patient populations, albeit in a geographic region experiencing rapid increases in patients presenting with COVID-19. The analyses of changes of processes of care and outcomes over time were not comparative, but rather descriptive, and we are unable to make inferences of the effect of higher amounts of NIPPV use and PEEP on improved outcomes. The observational nature of the study limits our ability to say with confidence that the protocol is effective and which aspects of the protocol provided the greatest benefit. The limited number of regression analyses performed in this study raises the possibility of a type I error. Finally, the analysis was conducted using existing data in the database and cannot account for the possibility of patients not yet entered into the database late in the observation period. In a sensitivity analysis to attempt to account for this limitation, we eliminated approximately the last third of the observation period, which has a lower density of patients and encompasses a new calendar month. In this sensitivity analysis, the statistically significant association between pilot protocol implementation and VFDs remained in both unadjusted and adjusted analyses.

Conclusions
An academic safety net hospital caring for critically ill adults with COVID-19 and high rates of co-morbidities achieved in-hospital survival in most patients. Additionally, a care strategy of using NIPPV to avoid intubation and evidence-based ARDS management strategies applied, if intubated, may be safe for health-care workers and is associated with improved patient-centered outcomes. Future study is needed to confirm that this associated effect is consistent in a larger cohort over time.
Acknowledgments

Author contributions: Study concept and design: D. R. J., S. M., N. P., R. M., K. H., S. P. K. Acquisition of data: D. R. J., S. M., B. P. S., M. S. M., M. B., B. B., H. L., L. P., J. V., D. F. S., R. C., L. A., L. N., L. S., J. G., M. S., A. D., A. O. G., J. S. Analysis and interpretation of data: D. R. J., S. M., R. M., K. H., and S. P. K.; Drafting of the manuscript: D. R. J., K. I. H., S. P. K. Critical revision of the manuscript for important intellectual content: D. R. J., S. M., B. P. S., M. S. M., M. B., B. B., H. L., L. P., J. V., D. F. S., R. C., L. A., L. N., L. S., J. G., M. S., A. D., A. O. G., J. S., R. M., K. I. H., S. P. K.

Financial/nonfinancial disclosures: None declared.

Role of sponsors: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.

Additional information: The e-Appendix, e-Figures, and e-Tables can be found in the Supplemental Materials section of the online article.

References

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-534.

2. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-2059.

3. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. COVID-19 in critically ill patients in the Seattle region: case series. N Engl J Med. 2020;382(21):2012-2022.

4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond Engl. 2020;395(10229):1054-1062.

5. Taylor GI, Brenner W, Summer WR. Severe viral pneumonia in young adults: therapy with continuous positive airway pressure. Chest. 1976;66(9):722-728.

6. Vital FMR, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev. 2013;30(5):CD005351.

7. Osadnik CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;7(8860):CD004104.

8. Carrillo A, Ferrer M, Gonzalez-Diaz G, et al. Non-invasive ventilation in acute hypercapnic respiratory failure caused by obesity hyperventilation syndrome and chronic obstructive pulmonary disease. Am J Respir Crit Care. 2012;186(12):1279-1285.

9. Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med. 2020;48(6):e440-e469.

10. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342(18):1301-1308.

11. Wiedemann HP, Wheeler AP, et al. Network NH Lung, and Blood Institute acute respiratory distress syndrome (ARDS) clinical trials: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24):2564-2575.

12. Fan E, Sorbo LD, Goligher EC, et al. An official American Thoracic Society/European Society of Intensive Care Medicine Clinical Practice Guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2017;195(9):1253-1263.

13. Guérin C, Reignier J, Richard J-C, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159-2168.

14. Briel M, Meade M, Mercat A, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA. 2010;303(9):865-873.

15. Devlin JW, Skrobik Y, Gélinas C, et al. Executive summary: clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):1532-1548.

16. Schmidt GA, Girard TD, Kress JP, et al. Official Executive Summary of an American Thoracic Society/American College of Chest Physicians clinical practice guideline: liberation from mechanical ventilation in critically ill adults. Am J Respir Crit Care. 2016;195(1):115-119.

17. Brown CA, Mosier JM, Carlson JN, Gibbs MA. Pragmatic recommendations for intubating critically ill patients with suspected COVID-19. J Am Coll Emerg Physicians. 2020;1(2):80-84.

18. Marini JJ,Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020;323(22).

19. Schoenfeld DA, Bernard GR; Network A. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002;30(8):1772-1777.

20. Network NH Lung, and Blood Institute PETAL Clinical Trials, Moss M, Huang DT, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380(21):1997-2008.

21. Elm E von, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296.

22. Popescu I, Fang P, Coster E, Guo J, Jiang HJ. Comparison of 3 safety-net hospital definitions and association with hospital characteristics. JAMA Netw Open. 2019;2(8). e198577-e198577.

23. Herrell LA, Wong SL, Ye Z, Miller DC. Utilization and outcomes of inpatient surgery at safety-net hospitals. J Health Care Poor U. 2016;27(4):1872-1884.

24. Wedzicha JA, Miravitles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49(3):1600791.